| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/23/2005 | CN1193755C Fast disintegrated and stripped oral cilostazol tablt and its prepn process |
| 03/23/2005 | CN1193754C Sustained release oral preparations |
| 03/23/2005 | CN1193753C Ginkgo leaf extract and injection fluid containing same |
| 03/23/2005 | CN1193752C Tetrahydrolipstatin-containing compositions |
| 03/23/2005 | CN1193745C Salmon calcitonin snuff inhalant and its prepn method |
| 03/23/2005 | CN1193744C Slow releasing micro-encapsulation compound antioxidant |
| 03/23/2005 | CN1193743C Multilayer pharmaceutical product for release in the colon |
| 03/23/2005 | CN1193742C Method of producing morphologically uniform microcapsules |
| 03/23/2005 | CN1193741C Preparation method of water soluble anticancer medical microsphere |
| 03/23/2005 | CN1193740C Fast dispersing dosage forms free of mamal gelatin |
| 03/23/2005 | CN1193738C Herbal skin care paste |
| 03/23/2005 | CN1193734C Oral liquor capable of preventing dental caries and reliveing inflammation |
| 03/23/2005 | CN1193662C Mosquito repellent product and its production method |
| 03/22/2005 | US6869976 Dispersion or complexes of calcium sulfate in polymers such as polyethylene glycol or dextran sulfate; is a solid matrix due to hydration; especially containing an antibiotic for treating bone disorders |
| 03/22/2005 | US6869963 Stable pharmaceutical compositions containing an ACE inhibitor |
| 03/22/2005 | US6869948 For treatment of pain/chronic rheumatic diseases; antipyretics |
| 03/22/2005 | US6869942 Comprises formoterol and corticosteroid; for use in treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease |
| 03/22/2005 | US6869939 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| 03/22/2005 | US6869938 Gels for use as bioadhesives |
| 03/22/2005 | US6869772 Method for labeling individual cells |
| 03/22/2005 | US6869769 Utilizes at least one primer for analysis; automatic for massed screening and the discovery of sequence variants of known virons, undetected virons and others |
| 03/22/2005 | US6869618 Process for preparing tannate liquid and semi-solid dosage forms |
| 03/22/2005 | US6869617 Dissolving the organic compound in the water-miscible first solvent to form a solution, mixing solution with second solvent to define a pre-suspension; adding energy to the pre-suspension to form particles |
| 03/22/2005 | US6869615 Enterically coated to prevent gastrointestinal side effects |
| 03/22/2005 | US6869614 A gum, lollipop and lozenge having at least two separate components, with at least one of such components containing amounts of herbal, medicinal and/or mineral elements or combinations thereof to enhance metabolism |
| 03/22/2005 | US6869607 Vaccine formulations |
| 03/22/2005 | US6869590 Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque |
| 03/22/2005 | US6869588 Stimulus sensitive gel with radioisotope and methods of making |
| 03/22/2005 | US6869551 Focused acoustic radiation serves to eject droplets containing a compound of interest dissolved in a solvent. The droplets are subjected to a condition that allows for the compound of interest to precipitate out of solution |
| 03/22/2005 | CA2379672C Biodegradable poly(alkylene oxide)-poly(p-dioxanone) block copolymer soluble in organic solvents, and drug delivery composition comprising same |
| 03/22/2005 | CA2209673C Solid medicament form with active agent distributed in polymer material |
| 03/22/2005 | CA2088305C Water-in-oil emulsions |
| 03/18/2005 | CA2481624A1 Adhesive structures for attachment to skin |
| 03/17/2005 | WO2005024687A1 Medicine dosage management method, medicine, and medicine dosage management device |
| 03/17/2005 | WO2005023929A2 Granule |
| 03/17/2005 | WO2005023906A1 Hyaluronic acid modification product and drug carrier therefrom |
| 03/17/2005 | WO2005023304A2 Antimalarial compositions and manufacturing process thereof |
| 03/17/2005 | WO2005023293A1 Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere |
| 03/17/2005 | WO2005023283A1 Ophthalmic composition |
| 03/17/2005 | WO2005023282A1 Nanoparticle containing physiologically active protein or peptide, process for producing the same and external preparation comprising the nanoparticle |
| 03/17/2005 | WO2005023269A1 Medicament compositions comprising a heterocyclic compound and an anticholinergic |
| 03/17/2005 | WO2005023268A1 Application assembly for medicaments that are to be applied to the skin and packaging that is used as an application assembly |
| 03/17/2005 | WO2005023262A1 Oral itraconazole composition which is not affected by ingested food and process for preparing same |
| 03/17/2005 | WO2005023259A1 Itraconazole solution |
| 03/17/2005 | WO2005023252A1 Method of increasing the extent of absorption of tizanidine by combined intake with food |
| 03/17/2005 | WO2005023249A1 Novel orally administered dosage form for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -ethyl proprionate and salts thereof |
| 03/17/2005 | WO2005023236A1 Phenylephrine tannate, pyrilamine tannate, and dextromethorphan tannate salts in pharmaceutical compositions |
| 03/17/2005 | WO2005023233A2 Antimicrobial compositions and methods |
| 03/17/2005 | WO2005023230A1 Composition containing nanoparticles containing water-soluble basic drug encapsulated therein |
| 03/17/2005 | WO2005023229A1 Active substance pellets containing capsules and having different release profiles |
| 03/17/2005 | WO2005023228A1 Osmotic delivery of therapeutic compounds by solubility enhancement |
| 03/17/2005 | WO2005023227A2 Nicotine formulations and use thereof |
| 03/17/2005 | WO2005023226A1 Buccal drug delivery |
| 03/17/2005 | WO2005023225A1 Cilostazol adsorbate |
| 03/17/2005 | WO2005023224A1 Preparation method for sustained release microspheres using a dual-feed nozzle |
| 03/17/2005 | WO2005023223A2 Orally administrable dosage form for poorly soluble acids and amphoteric active ingredients |
| 03/17/2005 | WO2005023222A1 Pharmaceutical composition with improved solubility and fluidity |
| 03/17/2005 | WO2005023221A1 Clarithromycin formulations having improved biovailability |
| 03/17/2005 | WO2005023220A1 Non-polar photosensitizer formulations for photodynamic therapy |
| 03/17/2005 | WO2005023219A2 Method for the production of homogeneous liposomes and lipoplexes |
| 03/17/2005 | WO2005023218A1 Emulsion of perfluororganic combination with a function of gastransport |
| 03/17/2005 | WO2005023217A2 Granular sustained release preparation and production thereof |
| 03/17/2005 | WO2005023215A2 Particles shaped as platelets |
| 03/17/2005 | WO2005023184A2 Antibiotic product, use and formulation thereof |
| 03/17/2005 | WO2005023181A2 Polymeric systems for controlled drug therapy |
| 03/17/2005 | WO2005023176A2 Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides |
| 03/17/2005 | WO2005023175A2 Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound |
| 03/17/2005 | WO2005014814A3 5’-and 3’-capped aptamers and uses therefor |
| 03/17/2005 | WO2005011635A3 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| 03/17/2005 | WO2005010240A3 Low temperature methods for hermetically sealing reservoir devices |
| 03/17/2005 | WO2005004919A3 Extended release systems for macrolide antibiotics |
| 03/17/2005 | WO2005004838A8 Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof |
| 03/17/2005 | WO2005002643A3 Method and products for delivering biological molecules to cells using multicomponent nanostructures |
| 03/17/2005 | WO2004108116A3 Stabilized particle dispersions containing surface-modified inorganic nanoparticles |
| 03/17/2005 | WO2004103408A3 Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
| 03/17/2005 | WO2004103347A3 Production of small particles |
| 03/17/2005 | WO2004103339A3 Improved metered dose inhaler |
| 03/17/2005 | WO2004096266A8 Improved physical stability of insulin formulations |
| 03/17/2005 | WO2004089336A3 Drug delivery systems comprising an encapsulated active ingredient |
| 03/17/2005 | WO2004087213A8 Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant |
| 03/17/2005 | WO2004082708A3 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
| 03/17/2005 | WO2004082633A3 A method of treating a systemic disease |
| 03/17/2005 | WO2004075843A3 Glycosolated enkephalin agents |
| 03/17/2005 | WO2004069223A3 Pharmaceutical compositions comprising immunosuppressants and uses thereof |
| 03/17/2005 | WO2004066910A3 Controlled release modifying complex and pharmaceutical compositions thereof |
| 03/17/2005 | WO2004049358A3 Multifunctional particulate material, fluid, and composition |
| 03/17/2005 | WO2004043486A8 An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism |
| 03/17/2005 | WO2004032843A3 Mucoadhesive tetracycline formulations |
| 03/17/2005 | WO2003101425A3 Therapeutic agent-containing polymeric nanoarticles |
| 03/17/2005 | WO2002100343A3 N-terminally truncated galectin-3 and antibodies for treating cancer |
| 03/17/2005 | US20050059956 Devices for intraocular drug delivery |
| 03/17/2005 | US20050059742 Such as 5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one potassium salt, or a prostaglandin derivative, or 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809) |
| 03/17/2005 | US20050059740 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
| 03/17/2005 | US20050059719 Solid dosage formulation containing a Factor Xa inhibitor and method |
| 03/17/2005 | US20050059707 Benzoyl-, indanoyl- or tetrahydronaphthoyl-oxy (or thio) nicotinic acid derivatives; a kit comprising two chambers for mixing the compound in solid form with a topical carrier within seven days prior to topical administration |
| 03/17/2005 | US20050059701 Oral dosage form contains povidone or copovidone binder; HCl-free or non-hygroscopic filler; serotonin reuptake inhibition; stable without lose its hardness after storage |
| 03/17/2005 | US20050059674 reducing granulation tissue in humans having otitis and an open tympanic membrane comprising topically applying an aqueous suspension composition containing a combination of ciprofloxacin and dexamethasone |
| 03/17/2005 | US20050059667 pH-dependent binder controls rate of dissolution of tablet; cardiovascular disease |
| 03/17/2005 | US20050059645 Methods for the treatment of male and female sexual dysfunction |
| 03/17/2005 | US20050059644 Including one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid |